skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

80 Total results for product and free and sample content found

Datamonitor Healthcare, Scrip, Trialtrove, In...

The tumor-agnostic developer’s toolkit

The tumor-agnostic developer’s toolkit

The tumor-agnostic developer’s toolkit

Datamonitor Healthcare, Biomedtracker, Pharma...

RNA Targeting Poised To Share The Spotlight With Gene Therapy

Blog

As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.

Topic Cell and gene therapy

Datamonitor Healthcare, Biomedtracker

Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

Citeline

Rescuing The Opioid Crisis

Blog

Recent news of the Ohio State ruling on the opioid litigation trial against Johnson & Johnson shed new light on the complex opioid addiction crisis in the US.

Topic Drug development landscape

Trialtrove

Clinical Trial Endpoints Made Easy!

Survival_Data_Boost_Lilly_Novartiss_CDK46_Assault_On_Pfizers_Ibrance_In_Metastatic_Breast_Cancer

Trialtrove recently released a major enhancement that indexes primary and secondary endpoints evaluated in clinical trials. 

Topic Drug development landscape

Datamonitor Healthcare

mHealth and Research in Oncology

mHealth and Research in Oncology

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare, Biomedtracker

Gene therapy manufacturers

Gene therapy manufacturers

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker, Datamonitor Healthcare

Deconstructing the KRAS+ market opportunity

Deconstructing the KRAS+ market opportunity

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic BioPharmaceutical Drug review

Datamonitor Healthcare, Pharmaprojects, Biome...

Opening the door for cell therapy in solid tumors

Opening the door for cell therapy in solid tumors

In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.

Topic Cancer Cell and gene therapy

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: